NEWS

Manufacturing of AAV Vectors for Gene Therapy
Genetic Engineering & Biotechnology News
The successes seen in a number of clinical studies on viral vector-based gene therapies (AAV, retroviral, and lentiviral vectors) are well documented, with an ever-broadening pipeline of products entering late-phase clinical trials and hopefully …

CRISPR Platform Scans DNA to Predict Off-Target Effects
Genetic Engineering & Biotechnology News (press release)
For example, the popular gene-editing tool known as CRISPR could go astray, altering genes other than the ones it was meant to alter. If only CRISPR’s potential slips could be foreseen! Then, perhaps, they could be avoided, and CRISPR would realize its …
Mosquito suppression on ‘continental scale’ could be possible with CRISPRGenetic Literacy Project
New Gene Editing Technology Suppresses Wild Insects, Could …Science World Report

all 4 news articles »

CRISPR Platform Scans DNA to Predict Off-Target Effects
Genetic Engineering & Biotechnology News (press release)
For example, the popular gene-editing tool known as CRISPR could go astray, altering genes other than the ones it was meant to alter. If only CRISPR’s potential slips could be foreseen! Then, perhaps, they could be avoided, and CRISPR would realize its …
This New Gene-Editing Technique Can Spot CRISPR’s MistakesFuturism
Bringing bacteria’s defense into focusCornell Chronicle
Novel Technique Enables Safer Gene-Editing Therapy Using CRISPR, Says StudyScicasts (press release) (blog)
The Cerbat Gem –BNB Daily (blog) –Markets Daily
all 25 news articles »

TissueGene Awarded $750000 Maryland Stem Cell Grant for Invossa™ Clinical Study
PR Newswire (press release)
ROCKVILLE, Md., June 30, 2017 /PRNewswire/ — TissueGene, Inc. (“TissueGene”), a Maryland-based regenerative medicine company, announced today that the Maryland Stem Cell Research Fund (MSCRF) has awarded TissueGene a clinical grant for …

and more »

TissueGene Awarded $750000 Maryland Stem Cell Grant for Invossa™ Clinical Study
PR Newswire (press release)
ROCKVILLE, Md., June 30, 2017 /PRNewswire/ — TissueGene, Inc. (“TissueGene”), a Maryland-based regenerative medicine company, announced today that the Maryland Stem Cell Research Fund (MSCRF) has awarded TissueGene a clinical grant for …

and more »

Chinese company completes acquisition of US firm providing immunotherapy for prostate cancer
Xinhua
At the heart of the deal is Dendreon’s lead product, Provenge, the only cellular immunotherapy approved so far by the U.S. Food and Drug Administration (FDA) for treatment of asymptomatic or minimally symptomatic metastatic castration-resistant …

How These Drugmakers Are Making Science Fiction A Reality In Cancer
Investor’s Business Daily
“CAR–T is the best form of immuno-oncology,” according to Janney analyst Debjit Chattopadhyay. Immuno-oncology drugs harness the immune system to treat cancer. To create the drug, researchers extract the immune system cells from a patient’s blood.